Edition:
United States

Exelixis Inc (EXEL.O)

EXEL.O on Nasdaq

17.08USD
12:06pm EST
Change (% chg)

$0.17 (+1.01%)
Prev Close
$16.91
Open
$17.00
Day's High
$17.25
Day's Low
$16.86
Volume
1,707,557
Avg. Vol
6,649,274
52-wk High
$18.29
52-wk Low
$3.55

Latest Key Developments (Source: Significant Developments)

Exelixis says European commission approves Cabometyx
Wednesday, 14 Sep 2016 01:00am EDT 

Exelixis Inc : European Commission approves Cabometyx tablets for the treatment of advanced renal cell carcinoma following VEGF-targeted therapy . Says approval of Cabometyx in European Union triggers $60 million milestone payment to Exelixis under licensing agreement with Ipsen . Says approval allows for marketing of cabometyx in all 28 member states of european union, Norway and Iceland . Says approval is based on results of large, randomized phase 3 meteor trial .Says EC approval of cabometyx allows further development of cabometyx indications outside of United States, Canada and Japan.  Full Article

Exelixis says entered privately negotiated exchange agreements with certain holders
Monday, 22 Aug 2016 08:54am EDT 

Exelixis Inc : Entered into privately negotiated exchange agreements with certain holders of 4.25 pct convertible senior subordinated notes due 2019 . Holders agreed to exchange an aggregate principal amount of approximately $71.3 million of notes held by them . Exchange for an aggregate of approximately 13.4 million shares of the company’s common stock Source: (http://bit.ly/2bbqXzk ) Further company coverage: [EXEL.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Exelixis Q2 loss per share $0.16
Wednesday, 3 Aug 2016 04:06pm EDT 

Exelixis Inc : Exelixis announces second quarter and year to date 2016 financial results and provides corporate update . Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S . Q2 revenue view $16.4 million -- Thomson Reuters I/B/E/S . Q2 loss per share $0.16 . Q2 revenue $36.3 million versus $8.0 million .Says is refining its guidance that operating expenses for full year 2016 will be between $250 million and $270 million.  Full Article

EU Medicines Agency recommends approval of two new cancer drugs
Friday, 22 Jul 2016 07:21am EDT 

EU Medicines Agency : EU medicines agency recommendations for july 2016 . Recommends approval of Exelixis Inc’S cabozantinib to treat advanced renal cell carcinoma .Recommends Approval Of Baxter International Inc’S Irinotecan to treat pancreatic cancer.  Full Article

Exelixis, Ipsen post results from advanced renal cell carcinoma study
Monday, 6 Jun 2016 07:30am EDT 

Exelixis Inc : Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CABOMETYX(tm) (cabozantinib) tablets in advanced renal cell carcinoma at 2016 ASCO annual meeting .Additional data from pivotal meteor trial underscore clinically meaningful benefit of CABOMETYX across subgroups of patients.  Full Article

Exelixis and Ipsen announce Phase 3 trial results of CABOMETYX
Monday, 6 Jun 2016 02:31am EDT 

Exelixis Inc and Ipsen :Announced on Sunday Phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO.  Full Article

Exelixis and Ipsen announce Phase 3 trial results of CABOMETYX
Sunday, 5 Jun 2016 07:36am EDT 

Exelixis Inc and Ipsen :Announced on Sunday Phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO.  Full Article

Ipsen SA says Exelixis Inc reported positive top-line results from Cabosun phase 2 trial of Cabozantinib
Monday, 23 May 2016 02:31pm EDT 

Ipsen Sa says Exelixis Inc: reported positive top line results from Cabosun phase 2 trial of Cabozantinib in patients with untreated advanced renal cell carcinoma . Trial met its primary endpoint, statistically significant improvement in progression-free survival for Cabozantinib compared with Sunitinib .Safety data in Cabozantinib-treated arm of study were consistent with those observed in previous studies in patients with advanced rcc.  Full Article

Exelixis says phase 2 trial met primary endpoint for advanced renal cell carcinoma
Monday, 23 May 2016 09:02am EDT 

Exelixis : Trial met its primary endpoint .Announces results from randomized phase 2 trial cabosun demonstrate cabozantinib significantly improved progression free survival versus sunitinib in previously untreated advanced renal cell carcinoma.  Full Article

Exelixis and Ipsen enter into exclusive licensing agreement
Tuesday, 1 Mar 2016 01:00am EST 

Ipsen SA:Exelixis and Ipsen enter into exclusive licensing agreement to commercialize and develop novel cancer therapy cabozantinib in regions outside the United States, Canada and Japan.Ipsen will have exclusive commercialization rights for current and potential future cabozantinib indications outside the United States, Canada and Japan.Exelixis will receive $200 million upfront payment and subsequent regulatory and commercial milestones ‍​.The agreement also includes up to $545 million of potential commercial milestones and provides for Exelixis to receive tiered royalties up to 26 pct on Ipsen`s net sales of cabozantinib in its territories.  Full Article

BRIEF-Exelixis announces Q3 and YTD 2016 financial results

* Exelixis announces third quarter and year to date 2016 financial results and provides corporate update